{
    "clinical_study": {
        "@rank": "90571", 
        "arm_group": {
            "arm_group_label": "Abiraterone acetate", 
            "arm_group_type": "Experimental", 
            "description": "Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate."
        }, 
        "brief_summary": {
            "textblock": "The addition of abiraterone acetate to standard treatment of radiotherapy and short-term\n      androgen deprivation will increase the frequency of undetectable PSA."
        }, 
        "brief_title": "Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a single arm two-site study of 37 men with unfavorable prostate cancer (defined as\n      having a single high risk factor). Patients will concurrently initiate 6 months of\n      standard-of-care GNRH agonist therapy and once daily abiraterone acetate/prednisone. After 2\n      months of lead-in hormonal treatment, definitive standard-of-care prostate/seminal vesicle\n      radiotherapy will be delivered, to a total dose of 75-80 Gy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Gleason Score 7 with PSA < 20 ng/ml and T1-2b exam, or\n\n          -  Gleason Score 8-10, PSA \u2264 20 ng/ml and T1 exam, or\n\n          -  PSA 10.1-30 ng/ml with GS < 7 and T1 exam, or\n\n          -  Clinical T3 with Gleason Score < 7 and PSA < 10 ng/ml. T3 clinical stage may be based\n             on exam or imaging (MRI, CT, ultrasound) prior to entry\n\n          -  ECOG Performance Status \u2264 1\n\n          -  Serum testosterone >150 ng/dl prior to start of androgen deprivation\n\n          -  CBC with differential with adequate bone marrow function defined as follows:\n\n          -  Absolute neutrophil count (ANC) \u2265 1,500 cells/mm3, Platelets > 100,000/\u00b5L and\n             Hemoglobin > 9g/dL\n\n          -  Serum potassium  \u2265  3.5 mEq/L\n\n          -  Serum albumin >  3.0 g/dl\n\n          -  Total bilirubin < 1.5 X of institutional upper limit of normal (ULN)\n\n          -  AST(SGOT)/ALT(SGPT) < 1.5 X ULN\n\n          -  Calculated creatinine clearance > 60 mL/min\n\n          -  Age > 18 years\n\n          -  Able to swallow a whole tablet and take abiraterone acetate on an empty stomach\n             (defined as no food for two hours before and one hour after abiraterone acetate\n             ingestion)\n\n          -  Ability to understand and sign a written informed consent document\n\n          -  Written authorization for use and release of health and research study information\n             has been obtained\n\n          -  Be willing/able to adhere to the prohibitions and restrictions specified in this\n             protocol\n\n          -  Subjects who have partners of childbearing potential must be willing to use a method\n             of birth control with adequate barrier protections as determined acceptable by the\n             principal investigator during the study and for 1 week after the last dose of\n             abiraterone acetate.\n\n        Exclusion Criteria:\n\n          -  Bone, visceral or soft tissue metastasis, including lymph nodes\n\n          -  Prior therapy for prostate cancer\n\n          -  Previous malignancy within 3 years other than non-melanomatous skin cancer and\n             non-muscle invasive bladder cancer\n\n          -  Previous pelvic radiotherapy that would prevent prostate/SV irradiation\n\n          -  Uncontrolled hypertension\n\n          -  History of gastrointestinal disorders that may interfere with the absorption of study\n             drug (including gastric bypass surgery)\n\n          -  Concurrent spironolactone use\n\n          -  Significant concurrent medical condition that would make prednisone/prednisolone use\n             contraindicated\n\n          -  Receiving any investigational agents currently or within 30 days prior to study\n             screening\n\n          -  Prior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate,\n             prednisone or their excipients\n\n          -  Active co-morbidity, defined as follows:\n\n               -  Chronic liver disease with cirrhosis (Child-Pugh B or C) or active hepatitis B\n                  or C\n\n               -  History of pituitary or adrenal dysfunction\n\n               -  Poorly controlled diabetes mellitus (A1c >9% or history of complications\n                  including peripheral neuropathy, end organ damage, hospitalization, amputation)\n\n               -  Clinically significant heart disease as evidenced by myocardial infarction, or\n                  arterial thrombotic events in the past 6 months, severe or unstable angina, or\n                  New York Heart Association (NYHA) Class III-IV heart disease or known cardiac\n                  ejection fraction measurement of < 50% at baseline.\n\n               -  Clinical evidence of active infection of any type, including active or\n                  symptomatic viral hepatitis.\n\n               -  Known immune deficiency and/or HIV-positive patients\n\n               -  Any medical condition that warrants long-term corticosteroid use in excess of\n                  study dose\n\n          -  Patients taking strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin,\n             rifabutin, rifapentine, phenobarbital)\n\n          -  Any condition that in the opinion of the Principal Investigator, would compromise the\n             well-being of the subject or the study or prevent the subject from meeting or\n             performing the study requirements"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717053", 
            "org_study_id": "Pro00044071"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abiraterone acetate", 
                "description": "1000 mg orally once a day for 6 months.", 
                "intervention_name": "Abiraterone acetate", 
                "intervention_type": "Drug", 
                "other_name": "Zytiga"
            }, 
            {
                "arm_group_label": "Abiraterone acetate", 
                "description": "Leuprolide acetate (22.5mg IM) or goserelin acetate (10.8mg SC) will be administered every 3 months for 2 doses", 
                "intervention_name": "Androgen deprivation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Abiraterone acetate", 
                "description": "Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy", 
                "intervention_name": "Radiation Therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Abiraterone acetate", 
                "description": "5 mg tablet once daily for 6 months.", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Androgens", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "William R Lee, MD", 
                    "phone": "919-668-5640"
                }, 
                "contact_backup": {
                    "email": "ellen.bratt@duke.edu", 
                    "last_name": "Ellen Bratt, RN", 
                    "phone": "919-684-7590"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "William R Lee, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bridget Koontz, MD", 
                    "phone": "919-668-5213"
                }, 
                "contact_backup": {
                    "email": "ellen.bratt@duke.edu", 
                    "last_name": "Ellen Bratt, RN", 
                    "phone": "919-684-7590"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27704"
                    }, 
                    "name": "Durham Regional Hospital"
                }, 
                "investigator": {
                    "last_name": "Bridget Koontz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer", 
        "overall_contact": {
            "email": "ellen.bratt@duke.edu", 
            "last_name": "Ellen Bratt, RN", 
            "phone": "919-684-7590"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Bridget Koontz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Undetectable PSA at 1 year from treatment initiation", 
            "measure": "Rate of undetectable PSA (<0.1 ng/ml)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717053"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PSA nadir values at 1 and 2 years", 
                "measure": "PSA nadir value", 
                "safety_issue": "No", 
                "time_frame": "1 year, 2 years"
            }, 
            {
                "measure": "Time to PSA nadir", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Disease progression defined as Phoenix RTOG definition of nadir + 2ng/ml or initiation of salvage therapy", 
                "measure": "Biochemical progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 2.5 years"
            }, 
            {
                "description": "Time to metastasis or systemic therapy", 
                "measure": "Metastasis or systemic therapy", 
                "safety_issue": "No", 
                "time_frame": "up to 2.5 years"
            }, 
            {
                "description": "Time to testosterone recovery", 
                "measure": "Testosterone recovery", 
                "safety_issue": "No", 
                "time_frame": "up to 2.5 years"
            }, 
            {
                "description": "Proportion of men with 1 and 2 year PSA < 1.5ng/ml in setting of non-castrate testosterone", 
                "measure": "PSA < 1.5ng/ml in setting of non-castrate testosterone", 
                "safety_issue": "No", 
                "time_frame": "1 year, 2 years"
            }, 
            {
                "description": "To evaluate the short and long term safety and tolerability of 6 months of abiraterone acetate with prednisone and ADT combined with standard RT in men with intermediate/lower high risk localized prostate cancer", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 7 months"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}